TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Na
Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

Genelux Corporation announced the appointment of Jason Litten, M.D., as Chief Medical Officer effective January 2, 2026. Dr. Litten brings over 20 years of biopharmaceutical experience and will oversee clinical development and medical strategy for Olvi-Vec, the company's oncolytic immunotherapy candidate currently in Phase 2/3 trials for ovarian and lung cancers.

Insights
WFCpC   neutral

Mentioned only as a conference host with no specific performance details


GNLX   positive

The appointment of an experienced CMO with a strong track record in oncology drug development signals confidence in the company's clinical programs and strengthens execution capabilities. The executive's background leading complex programs through late-stage trials is positive for advancing Olvi-Vec toward key regulatory milestones expected in 2026.